Hepatitis, Chronic clinical trials

The registry lists 83 studies for Hepatitis, Chronic across more than 10 countries. 10 are recruiting or about to start. 27 of them are mainly about Hepatitis, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 4 narrower conditions too, such as Hepatitis C, Chronic: 2,005 studies, 193 open.

Get an email when these change. Save the Hepatitis, Chronic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 48
Status unknown: 13
Recruiting: 9
Terminated: 8
Active, not recruiting: 2
Approved for marketing: 2

Phase

Phase 2: 22
Phase 1: 14
Phase 3: 12
Phase 4: 10

Where

United States: 34
France: 14
China: 13
Taiwan: 11
Spain: 11
Italy: 10

Who runs them

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Gilead Sciences (7) · Cytheris SA (4) · Bristol-Myers Squibb (3) · Pfizer (3) · Novartis Pharmaceuticals (2) · GlaxoSmithKline (2) · National Cancer Institute (NCI) (2)

What is being tested here

Drugs under test in Hepatitis, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Hepatitis B Virus Antisense Oligonucleotide AHB-137	2	0	2
Ribavirin	0	3	7
Sofosbuvir	0	1	3
Peginterferon alfa-2a	0	0	3
Interleukin 7	0	0	3
Bepirovirsen	0	2	2
Paritaprevir	0	1	2
Ombitasvir	0	1	2
Dasabuvir	0	1	2
Lamivudine	0	0	2

Drug classes tested here Reverse transcriptase inhibitors 5

Coming up

0phase 3 studies under way

2studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 2

May 2027Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions · AusperBio Therapeutics Inc.
Jul 2027VACcination of LIver Transplantation Candidates · Hospices Civils de Lyon

Who these studies take

Of the 9 Hepatitis, Chronic studies recruiting now, 2 (22%) set no upper age limit and 6 (67%) stop at 75 or younger. 1 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (22%) take healthy volunteers.

Recruiting studies that take each age, of 9
Age	Women	Men
10	1 (11%)	1 (11%)
18	9 (100%)	9 (100%)
30	9 (100%)	9 (100%)
40	9 (100%)	9 (100%)
50	9 (100%)	9 (100%)
65	7 (78%)	7 (78%)
75	5 (56%)	5 (56%)
85	3 (33%)	3 (33%)

Across all 83 studies, recruiting or not: 37% stop at 75 or younger and 20% at 65; 11% take children; 0% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

EXPANDED-ACCESS PROGRAM FOR THE TREATMENT OF CHRONIC HEPATITIS D WITH BRELOVITUGNov 6, 2026NCT07922733

Studies

Recruiting first, then most recently updated. Showing 50 of 83. Browse all 83 → or search them.